BNTX vs. LLY

Last updated Apr 1, 2026

Compare and contrast key facts about BioNTech SE (BNTX) and Eli Lilly and Company (LLY).

Performance

BNTX vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BioNTech SE (BNTX) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

BNTX vs. LLY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
BNTX BioNTech SE	-6.64%	-16.45%	7.97%	-29.74%	-40.40%	216.24%	140.61%	137.92%
LLY Eli Lilly and Company	-14.27%	40.25%	33.30%	60.91%	34.26%	66.08%	31.04%	23.63%

Fundamentals

Market Cap BNTX : $21.79B LLY : $825.96B
EPS BNTX : -$4.68 LLY : $22.96
PS Ratio BNTX : 7.52 LLY : 12.68
PB Ratio BNTX : 1.13 LLY : 31.13
Total Revenue (TTM) BNTX : $2.86B LLY : $65.18B
Gross Profit (TTM) BNTX : $2.22B LLY : $54.62B
EBITDA (TTM) BNTX : -$635.06M LLY : $27.94B

Returns By Period

In the year-to-date period, BNTX achieves a -6.64% return, which is significantly higher than LLY's -14.27% return.

BNTX

• 1D: 4.26%
• 1M: -19.37%
• YTD: -6.64%
• 6M: -9.88%
• 1Y: -2.39%
• 3Y*: -10.64%
• 5Y*: -4.40%
• 10Y*: —

LLY

• 1D: 3.74%
• 1M: -12.57%
• YTD: -14.27%
• 6M: 20.93%
• 1Y: 12.19%
• 3Y*: 39.90%
• 5Y*: 39.16%
• 10Y*: 30.92%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BNTX vs. LLY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BNTX

BNTX Risk / Return Rank: 37
BNTX Sharpe Ratio Rank: 39
BNTX Sortino Ratio Rank: 37
BNTX Omega Ratio Rank: 38
BNTX Calmar Ratio Rank: 36
BNTX Martin Ratio Rank: 36

LLY

LLY Risk / Return Rank: 51
LLY Sharpe Ratio Rank: 53
LLY Sortino Ratio Rank: 48
LLY Omega Ratio Rank: 49
LLY Calmar Ratio Rank: 53
LLY Martin Ratio Rank: 54

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BNTX vs. LLY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BioNTech SE (BNTX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BNTX	LLY	Difference
Sharpe ratio Return per unit of total volatility	-0.05	0.29	-0.34
Sortino ratio Return per unit of downside risk	0.29	0.69	-0.40
Omega ratio Gain probability vs. loss probability	1.04	1.10	-0.05
Calmar ratio Return relative to maximum drawdown	-0.21	0.42	-0.63
Martin ratio Return relative to average drawdown	-0.43	1.02	-1.45
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BNTX vs. LLY - Sharpe Ratio Comparison

The current BNTX Sharpe Ratio is -0.05, which is lower than the LLY Sharpe Ratio of 0.29. The chart below compares the historical Sharpe Ratios of BNTX and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BNTX	LLY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.05	0.29	-0.34
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.08	1.23	-1.30
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.04	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.43	0.56	-0.13

Correlation

The correlation between BNTX and LLY is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

BNTX vs. LLY - Dividend Comparison

BNTX has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.68%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BNTX BioNTech SE	0.00%	0.00%	0.00%	0.00%	2.43%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
LLY Eli Lilly and Company	0.68%	0.56%	0.67%	0.78%	1.07%	1.23%	1.75%	1.96%	1.94%	2.46%	2.77%	2.37%

Drawdowns

BNTX vs. LLY - Drawdown Comparison

The maximum BNTX drawdown since its inception was -82.08%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for BNTX and LLY.

Drawdown Indicators

	BNTX	LLY	Difference
Max Drawdown Largest peak-to-trough decline	-82.08%	-68.24%	-13.84%
Max Drawdown (1Y) Largest decline over 1 year	-30.40%	-30.26%	-0.14%
Max Drawdown (5Y) Largest decline over 5 years	-82.08%	-34.48%	-47.60%
Max Drawdown (10Y) Largest decline over 10 years	—	-34.48%	—
Current Drawdown Current decline from peak	-79.67%	-17.00%	-62.67%
Average Drawdown Average peak-to-trough decline	-55.53%	-19.25%	-36.28%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.03%	12.39%	+2.64%

Volatility

BNTX vs. LLY - Volatility Comparison

BioNTech SE (BNTX) has a higher volatility of 24.56% compared to Eli Lilly and Company (LLY) at 9.04%. This indicates that BNTX's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BNTX	LLY	Difference
Volatility (1M) Calculated over the trailing 1-month period	24.56%	9.04%	+15.52%
Volatility (6M) Calculated over the trailing 6-month period	33.33%	26.21%	+7.12%
Volatility (1Y) Calculated over the trailing 1-year period	50.44%	42.44%	+8.00%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	57.12%	32.14%	+24.98%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	77.11%	29.80%	+47.31%

Financials

BNTX vs. LLY - Profitability Comparison

The chart below illustrates the profitability comparison between BioNTech SE and Eli Lilly and Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

BNTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, BioNTech SE reported a gross profit of 568.72M and revenue of 898.89M. Therefore, the gross margin over that period was 63.3%.

LLY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a gross profit of 16.41B and revenue of 19.29B. Therefore, the gross margin over that period was 85.1%.

BNTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, BioNTech SE reported an operating income of -230.62M and revenue of 898.89M, resulting in an operating margin of -25.7%.

LLY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported an operating income of 8.78B and revenue of 19.29B, resulting in an operating margin of 45.5%.

BNTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, BioNTech SE reported a net income of -302.14M and revenue of 898.89M, resulting in a net margin of -33.6%.

LLY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a net income of 6.64B and revenue of 19.29B, resulting in a net margin of 34.4%.